Invitae adds Medneon's risk assessment tools to its education and clinical support offerings -- Easy-to-use software makes it easier for clinicians to use genetics to improve patient care -- News provided by Share this article SAN FRANCISCO, Feb. 24, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the addition of tools from Medneon, a digital health AI company, to its robust clinical workflow and patient education tools. The additional capabilities further support clinicians and patients with cancer by making it easier to determine ...